What are the best prescription weight loss pills?
Reviewed by Beverly Tchang, MD,
Written by Chimene Richa, MD
Reviewed by Beverly Tchang, MD,
Written by Chimene Richa, MD
last updated: Sep 30, 2024
8 min read
Here's what we'll cover
Here's what we'll cover
Obesity is a chronic medical condition that affects millions of people worldwide. And while BMI (body mass index) is not the be-all and end-all assessment of obesity (it’s not without its problems), more than 73% of adults over the age of 20 have measurements in the overweight or obese range in the United States. That’s more than two out of every three adults.
For some people, diet and exercise are not enough to lose weight and keep it off. This is where weight loss medication, including weight loss pills, comes in. When combined with diet and exercise, the best weight loss pills can help you lose weight—and keep it off—by:
Suppressing your appetite (decreasing your desire to eat)
Reducing how much fat you absorb from the foods you eat
Making you feel full faster within a meal and longer in between meals
What is the best weight loss pill for you? That depends. Continue reading to learn more about the strongest weight loss pills available today.
The strongest prescription weight loss pills
Antiobesity medications are most effective when combined with healthy lifestyle changes, such as improving your diet and exercise routine. Making those changes while taking prescription weight loss pills can lead to a significant amount of weight loss—between 3% to 9% over the course of one year. Some of the strongest weight loss pills available today include:
Naltrexone/bupropion (brand name Contrave)
Phentermine/topiramate (brand name Qsymia)
Orlistat (brand names Xenical, Alli)
Phentermine (brand names Adipex-P, Lomaira)
Naltrexone/bupropion (brand name Contrave)
In clinical trials, roughly half of people taking naltrexone/bupropion lost at least 5% of their body weight within one year. That’s twice as many people who implemented lifestyle changes alone. One analysis of these same clinical trials reported the overall average weight loss on naltrexone/bupropion to be a little over 4% relative to placebo.
Naltrexone treats drug and alcohol dependence, while bupropion can improve depression and help people quit smoking. The combination of these two medications may affect dopamine, a brain chemical. By doing so, this drug reduces food cravings and decreases your appetite.
Common side effects of naltrexone/bupropion include nausea, headaches, constipation, insomnia, vomiting, dizziness, and dry mouth. Some people also notice elevations in blood pressure and heart rate while using naltrexone/bupropion. Since this combo medication includes bupropion, an antidepressant, it may increase the risk of suicide in young adults with depression when they first start treatment (a known side effect of antidepressants).
People with uncontrolled high blood pressure, seizure disorders, eating disorders, chronic opioid use, and severe liver failure should avoid using this drug. Also, anyone who has used monoamine oxidase inhibitors (MAOIs) in the past 14 days should not take naltrexone/bupropion because of the risk of serious side effects and drug interactions.
Phentermine/topiramate (brand name Qsymia)
In clinical trials, 75% of people taking phentermine/topiramate lost at least 5% of their body weight within one year, compared with only 23% of those taking a placebo. One observational study of real-world practice found that people lost about 4% of their body weight within five months of starting phentermine/topiramate, and about 8% after one year—which translates to nearly 20 pounds.
Phentermine/topiramate is a combination of phentermine and the anti-seizure/anti-migraine drug topiramate; using both drugs together works better than either drug alone to reduce appetite. Because of phetnermine’s potential for abuse, the DEA considers it a scheduled drug.
You should avoid using phentermine/topiramate if you have kidney stones, acute angle glaucoma, heart arrhythmias, high blood pressure or coronary heart disease. Side effects include dry mouth, constipation, paraesthesias (numbness/tingling), depression, anxiety, and elevated heart rate.
Orlistat (brand names Xenical, Alli)
In one analysis, 44% of people taking orlistat lost at least 5% of their body weight within one year—nearly twice as many as those taking a placebo. Other studies have found that people taking orlistat lose at least 2% of their body weight within five months, and around 3% after one year.
Orlistat works by decreasing the absorption of fats from your food—it reduces fat absorption by up to 30%. Orlistat is available in prescription strength (brand name Xenical) and a lower strength over-the-counter formulation (brand name Alli).
Most of the side effects of orlistat affect your gastrointestinal (GI) system, including stomach rumbling, abdominal cramps, bloating, and constipation. Some of the more distressing GI effects include:
Passing gas (sometimes with oily spotting)
Diarrhea, loose stools, or greasy stools
Frequent bowel movements that are hard to control
Liver damage (rare effect)
Fortunately, most of these issues improve after using it for a while and you may avoid some of them by sticking to a low-fat diet. Other side effects include poor absorption of fat-soluble vitamins (vitamins A, D, E, and K) and kidney stones.
Phentermine (brand names Adipex-P, Lomaira)
People taking phentermine can lose over 7% of their body weight, or at least 8 pounds.
Phentermine is just one of the active ingredients in phentermine/topiramate. Phentermine is a nervous system stimulant that suppresses appetite. It’s one of the most commonly prescribed weight loss pills, and is FDA-approved for weight management on a short term basis (12 weeks). As a stimulant, phentermine is a controlled substance that has a potential risk of abuse and dependence.
People with anxiety disorders, heart disease, a history of seizures, glaucoma, or high blood pressure should not use phentermine. Side effects include headache, insomnia, dry mouth, dizziness, and increased heart rate and blood pressure.
Brand name(s) | Approved for chronic weight management? | Average weight loss | |
Naltrexone/bupropion | Contrave | Yes | 5% |
Phentermine/topiramate | Qsymia | Yes | 6.5%–8.5% |
Orlistat | Xenical, Alli | Yes | 3%–3.5% |
Phentermine | Adipex-P, Lomaira | No, only short-term use (3 months) | 7% |
Who is eligible for weight loss medications?
Most weight loss pills are meant for adults over 18 years old with the following, according to current guidelines:
Obesity with a BMI of 30 kg/m2 or more
Overweight with a BMI of 27 kg/m2 or more with a weight-related health problem, like high blood pressure, type 2 diabetes, or heart disease
The easiest way to determine your weight category is to measure your Body Mass Index (BMI). BMI is a measurement of your body weight in kilograms (1 kilogram equals 2.2 pounds) divided by your height in meters squared (1 meter equals about 3 feet 3 inches). You can easily calculate your BMI by clicking here. Using your BMI, you can determine which of the following categories applies to you:
If your BMI is higher than 25, you have an increased risk of several health conditions, including heart disease, stroke, diabetes, and severe COVID-19. Losing as little as 5–10% of your weight can significantly improve your health. Weight loss medications, in addition to diet, exercise, and lifestyle modifications, are appropriate for some people to help with their weight loss goals.
It’s important to keep in mind that BMI does not account for factors like sex, body composition, and more. Additionally, research to support BMI as an assessment tool lacks racial and ethnic diversity.
Many weight loss pills are contraindicated for certain health conditions or medications. For example, people who are pregnant or breastfeeding should not take weight loss pills. Other common contraindications include uncontrolled high blood pressure and MAO inhibitors.
Review the prescribing information for any weight loss pill you are considering, and be sure to tell your healthcare provider about any health conditions you have as well as any medications you are taking. Sharing this information with them can help them determine the best weight loss pill for you.
How well do weight loss pills work?
Unfortunately, there is no magic pill to cure obesity. However, weight loss pills can help make your weight loss journey more successful, especially when combined with diet and exercise. And, the strongest weight loss pills have been tested for efficacy and safety in clinical trials.
These FDA-approved weight loss pills mainly work by suppressing your appetite. Some do so by activating parts of your brain involved in appetite regulation—such as naltrexone/bupropion, phentermine/topiramate, and phentermine—leading to fewer cravings and less hunger. Others, such as orlistat, work by blocking how much fat you absorb from food, so you absorb fewer calories overall.
How much weight you lose on weight loss pills can depend on the medication and what other lifestyle changes you make. Improving your diet and increasing your physical activity may lead to more weight loss. In general, people tend to lose between 3%–9% of their body weight after one year of taking weight loss pills, in combination with lifestyle changes.
How long do I need to take weight loss pills?
How long you need to continue taking weight loss pills depends on several factors and will vary from person to person. Depending on the side effects you experience and the success of your weight loss, your healthcare provider may need to adjust your dosage.
If your weight loss is successful and you don’t experience negative side effects, your healthcare provider may recommend taking weight loss pills long-term to help you keep the weight off. If you take your medication as prescribed and aren’t seeing results, your healthcare provider may prescribe you a different weight loss pill.
That said, the Food and Drug Administration (FDA) has approved certain weight loss pills for short-term vs. long-term use. As we mentioned above, phentermine is only FDA-approved for short-term use (up to 12 weeks). For long-term weight management, the FDA has approved three weight loss pills: phentermine/topiramate (Qsymia), naltrexone/bupropion (Contrave), and orlistat (Xenical, Alli).
Other medications that may help with weight loss
The drugs mentioned above are the ones that carry FDA approval. However, other drugs may be used “off-label” to help with weight loss. Off-label simply means that a drug is being used for a condition that it was not originally approved to treat.
Take metformin for example. Metformin is approved to treat type 2 diabetes but is used off-label to treat prediabetes based on data from the Diabetes Prevention Program, which showed a reduction in diabetes incidence by 30%. Nowadays, metformin is also used off-label to treat other conditions, like obesity, where it can cause up to 7% weight loss.
Antidepressants, drugs used to treat depression, are another class of medications that may help people lose weight. Bupropion, one of the drugs in the FDA-approved weight loss medicine Contrave, is an antidepressant that may aid weight loss.
Other weight loss treatments
Other options are available if prescription weight loss medications aren’t right for you.
Weight loss surgery
While surgery is the most invasive form of weight management, many of these procedures have been shown to help with weight loss, including:
Gastric banding: an inflatable band is placed around the stomach to create a smaller pouch, effectively reducing how much food you can eat and makes you feel fuller faster
Sleeve gastrectomy: most of your stomach is removed in this procedure, leaving you with a smaller stomach that it takes less food to feel full. It has the added benefit of affecting the gut hormones that play a role in hunger, feeling full, and blood sugar control.
Gastric bypass: also called Roux-en-Y gastric bypass, is a complicated surgery that reduces the size of your stomach and rearranges the small intestine to decrease calorie absorption. It can also affect your gut hormones.
Weight loss surgery is an effective option to manage your weight, but it does come with a risk of side effects and potential complications, such as nausea, vomiting, heartburn, abdominal pain, and infections. Some of these procedures can increase your risk for nutrient deficiencies like vitamin B12, iron, and folate deficiencies.
Will I gain weight back if I stop weight loss medication?
Unfortunately, even the strongest weight loss pills only work as long as you take them— when you stop them, you will likely gain weight back. Think of medications as another tool to manage your weight–just like diet and exercise. If you stop exercising, you are likely to gain weight back; similarly, stopping the medication can result in weight regain as well.
Do weight loss pills replace diet and exercise?
As much as we may wish, weight loss pills shouldn’t replace diet and exercise. Weight loss drugs should be part of a comprehensive treatment plan that includes lifestyle modifications, like diet and exercise, counseling, and behavioral interventions. Adding lifestyle changes may also help you minimize weight regain if you stop the weight loss pills.
People taking weight loss pills along with lifestyle modifications lose, on average, 7–10% of their initial weight after one year. These compounding effects may improve your risk of multiple health problems like type 2 diabetes and high blood pressure.
Weight loss pills may be the added boost you need to help you lose weight. However, they’re not for everyone. Talk to your healthcare provider about prescription medications for weight management to determine if any are right for you.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Alonso-Pedrero, L., Bes-Rastrollo, M., & Marti, A. (2019). Effects of antidepressant and antipsychotic use on weight gain: a systematic review. Obesity Reviews, 20(12), 1680-1690. doi: 10.1111/obr.12934. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31524318/
Apovian, C. M., Aronne, L. J., Bessesen, D. H., et al. (2015). Pharmacological management of obesity: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 100(2), 342–362. doi: 10.1210/jc.2014-3415. Retrieved from https://pubmed.ncbi.nlm.nih.gov/25590212/
Aronne, L. J., Wadden, T. A., Peterson, C., et al. (2013). Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring, Md.), 21(11), 2163–2171. https://doi.org/10.1002/oby.20584. Retrieved from https://onlinelibrary.wiley.com/doi/10.1002/oby.20584
Cohen, J. B. & Gadde, K. M. (2019). Weight Loss Medications in the Treatment of Obesity and Hypertension. Current Hypertension Reports, 21(2), 16. doi: 10.1007/s11906-019-0915-1. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415530/
DailyMed. (2023). Orlistat- capsule. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f81dfaeb-46d5-47ce-9ef6-19259f5ac61c
DailyMed-a. (2022). Qsymia- phentermine and topiramate capsule, extended release. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40dd5602-53da-45ac-bb4b-15789aba40f9
DailyMed-b. (2022). Saxenda- liraglutide injection, solution. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
DailyMed-c. (2022). Wegovy- semaglutide injection, solution. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet, 397(10278), 971–984. doi: 10.1016/S0140-6736(21)00213-0. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33667417/
Dimitriadis, G. K., Randeva, M. S., & Miras, A. D. (2017). Potential hormone mechanisms of bariatric surgery. Current Obesity Reports, 6(3), 253–265. doi: 10.1007/s13679-017-0276-5. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585994/
Fryar C. D., Carroll M. D., & Afful J. (2020). Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. NCHS Health E-Stats. Retrieved from https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/obesity-adult.htm
Gorgojo-Martínez, J. J., Basagoiti-Carreño, B., Sanz-Velasco, A., et al. (2019). Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study. International Journal of Clinical Practice, 73(11), e13399. doi: 10.1111/ijcp.13399. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31397946/
Grabarczyk, T. R. (2018). Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration. Pharmacotherapy, 38(1), 19–28. doi: 10.1002/phar.2048. Retrieved from https://pubmed.ncbi.nlm.nih.gov/29044720/
Greenway, F. L., Aronne, L. J., Raben, A., et al. (2018). A randomized, double‐blind, placebo‐controlled study of gelesis100: A novel nonsystemic oral hydrogel for weight loss. Obesity: A Research Journal, 27(2), 205-216. https://doi.org/10.1002/oby.22347. Retrieved from https://onlinelibrary.wiley.com/doi/full/10.1002/oby.22347
Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England), 376(9741), 595–605. doi: 10.1016/S0140-6736(10)60888-4. Retrieved from https://pubmed.ncbi.nlm.nih.gov/20673995/
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., et al. (2020). A randomized, controlled trial of liraglutide for adolescents with obesity. The New England Journal of Medicine (NEJM), 382(22), 2117–2128. doi: 10.1056/NEJMoa1916038. Retrieved from https://pubmed.ncbi.nlm.nih.gov/32233338/
Khera, R., Murad, M. H., Chandar, A. K., et al. (2016). Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA, 315(22), 2424. doi: 10.1001/jama.2016.7602. Retrieved from https://pubmed.ncbi.nlm.nih.gov/27299618/
LeBlanc, E. S., Patnode, C. D., Webber, E. M., et al. (2018). Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA, 320(11), 1172–1191. doi: 10.1001/jama.2018.7777. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30326501/
Lupoli, R., Lembo, E., Saldalamacchia, G., et al. (2017). Bariatric surgery and long-term nutritional issues. World Journal of Diabetes, 8(11), 464–474. doi: 10.4239/wjd.v8.i11.464. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700383/
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine, 375(4), 311–322. doi: 10.1056/NEJMoa1603827. Retrieved from https://pubmed.ncbi.nlm.nih.gov/27295427/
MedlinePlus. (n.d.). Obesity. Retrieved from https://medlineplus.gov/obesity.html
Perreault, L. (2021) Obesity in adults: Drug therapy. UpToDate. Retrieved from https://www.uptodate.com/contents/obesity-in-adults-drug-therapy
Pullman, J., Darsow, T., & Frias, J. P. (2006). Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vascular Health and Risk Management, 2(3), 203-212. doi: 10.2147/vhrm.2006.2.3.203. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993989/
Tchang, B. G., Aras, M., Kumar, R. B., et al. (2024). Pharmacologic Treatment of Overweight and Obesity in Adults. In K. R. Feingold (Eds.) et. al., Endotext. Retrieved from https://pubmed.ncbi.nlm.nih.gov/25905267/
U.S. Food and Drug Administration (FDA). (2020). FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market
Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. doi: 10.1056/NEJMoa2032183. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33567185/
Yanovski, S. Z. & Yanovski, J. A. (2014). Long-term Drug Treatment for Obesity. JAMA, 311(1), 74. doi: 10.1001/jama.2013.281361. Retrieved from https://pubmed.ncbi.nlm.nih.gov/24231879/
Yerevanian, A. & Soukas, A. A. (2019). Metformin: mechanisms in human obesity and weight loss. Current Obesity Reports, 8(2), 156-164. doi: 10.1007/s13679-019-00335-3. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520185/